News & Medical Papers
For current guidelines and updates from within the arrhythmia healthcare community please visit Arrhythmia Watch.
'New' Oral Anticoagulant Stroke-Protection Benefits in AF Cut Across Subgroups in Meta-Analysis
medscape.com, 5 December 2013
LONDON, UK — Collectively, four new oral anticoagulants (NOACs) protect against stroke or systemic embolism better than warfarin and compare favorably on safety in patients with atrial fibrillation (AF), concludes a meta-analysis of four big randomized trials, all major showcases for the agents' potential value in AF.
Final Scope issued on NICE public health guidance Independence and mental wellbeing (including social and emotional wellbeing) for older people
NICE, November 2013
Invitation to apply for the position of Standing committee member for the Clinical Guideline Rapid Updates Standing Committee B-pilot programme
NICE, November 2013
The National Institute for Health and Care Excellence (NICE) is a world leader in setting standards for high quality health and social care and for promoting healthy living. We provide authoritative, evidence-based guidance on the most effective ways to diagnose, treat and prevent disease and ill health.
ICD remote patient monitoring technology underused
healio.com, 4 December 2013
Fewer than half of patients who receive an implantable cardioverter defibrillator capable of remote patient monitoring use the technology within 180 days of implant, researchers reported in a recent study.
GARFIELD provides snapshot into real world of AF
Preliminary results from a 'real world' registry, GARFIELD, looking at newly-diagnosed patients with atrial fibrillation (AF) at risk for stroke, were presented at the meeting. Little is known about AF management and outcomes outside clinical studies and the registry will follow patients globally for up to six years. Early results show oral anticoagulants are being under prescribed in high-risk patients. Drs Henry Purcell and Henry Oluwasefunmi Savage discuss the registry findings in our BJC podcast.
View podcast now
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
EHRA, November 2013
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF).
Surrogates often make call to deactivate heart devices
uk.reuters.com, 26 July 2013
People who have implanted heart devices rarely have advance directives indicating whether they want them deactivated near the end of life, according to a new study. So the decision often has to be made by loved ones.
NICE Clinical guidelines, CG172 - Issued: November 2013
MI - secondary prevention: secondary prevention in primary and secondary care for patients following a myocardial infarction.Read more
Daiichi blood thinner safer, as effective as warfarin: study
uk.reuters.com, 19 November 2013
A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.
More, Faster Hypothermia No Better After Cardiac Arrest
medpagetoday.com, 17 November 2013
Strategies to cool out-of-hospital cardiac arrest patients more or faster had little extra impact on outcomes, two trials showed.
Resveratrol derivative shows promise in treating atrial fibrillation
cxvascular.com, 30 October 2013
A new study published in the British Journal of Pharmacology has shown that a new medication based on resveratrol—a compound found in red wine and nuts—is an effective inhibitor of several potential targets involved in atrial fibrillation development.
Radiation exposure in supraventricular tachycardia ablation reduced with minimally fluoroscopic mapping system
cxvascular.com, 8 November 2013
Radiofrequency ablation of supraventricular tachycardia guided by the non-fluoroscopic Ensite NavX mapping system (St Jude Medical) has shown lower levels of ionising radiation exposure for the patient and for the operator compared with conventional catheter ablation, according to preliminary results from the NO-PARTY Italian trial.
Magnetic analogue of ECG shows 89% accuracy diagnosing long QT syndrome in human foetuses
cxvascular.com, 13 November 2013
A first-of-its-kind study, published on 11 November in Circulation, has found that foetal magnetocardiography (fMCG)—the magnetic analogue of electrocardiograms (ECG)—may help to diagnose and possibly treat in utero long QT syndrome. Results using fMCG show 89% accuracy diagnosing long QT syndrome in the womb.
ECG Methodical Analysis
bjcardio.co.uk, September 2013
In this new regular series ‘ECGs for the fainthearted’ Dr Heather Wetherell will be interpreting ECGs in a non-threatening and simple way. She hopes this will help keep the art alive in primary care. In this first article, she looks at ECG methodical analysis.
Cardiomyopathy - clinical review
gponline.com, 8 November 2013
Discussing the diagnosis, management and prognosis of cardiomyopathy. By Dr cardiologist Dr Rajiv Sankaranarayanan.
Calon (Catheter Ablation: Linking Outcomes to NICE)
CALON is making progress, with negotiations underway to access the data needed a pilot project which will link patient information from different sources to give improved information on cardiac ablation.
AFib may spark MI
medpagetoday.com, 4 November 2013
Although myocardial infarction is a known risk factor for the development of atrial fibrillation, the relationship might work the other way around, too, researchers found.
Clinical strategies for selecting oral anticoagulants in atrial fibrillation
cxvascular.com, 17 October 2013
Patients with atrial fibrillation have a five- to seven-fold greater risk of stroke than the general population, and approximately 20% of ischaemic strokes are due to this arrhythmia. Vitamin K antagonists such as warfarin have been the long-standing anticoagulants for stroke prevention in atrial fibrillation.
Discrepancies in CRT-ICD battery longevity
cxvascular.com, 17 October 2013
An independent study demonstrates significant differences in battery longevity between contemporary cardiac resynchronisation therapy (CRT) implantable cardioverter defibrillators (ICDs). The results, published in Europace, show that Boston Scientific and St Jude Medical devices had longer battery life compared with Medtronic devices.
Papworth Hospital cardiologist's work on cutting edge defibrillator contributes to international award
cambridge-news.co.uk, 30 October 2013
A life-saving defibrillator developed at Papworth Hospital has received the coveted Prix Galien in New York.
End-of-Life Care in Patients With Implantable Cardioverter Defibrillators
medscape.com, October 2013
Implantable cardioverter defibrillator (ICD)-delivered shocks can cause substantial distress, warranting consideration of ICD deactivation at end of life.
Novel anticoagulant prescriptions on the rise among elderly patients
healio.com, 27 October 2013
Prescriptions for novel oral anticoagulants in Canada have increased rapidly since their approval for the treatment of atrial fibrillation, particularly among patients aged 85 years or older, according to a recent report.
Key questions on syncope in older people
pulse-learning.co.uk, 17 October 2013
Gerontologists Professor Rose Anne Kenny and Dr Nigel Stout answer questions from GP Dr Mandy Fry on underlying causes of syncope, first-line investigations and prescribing fludrocortisone.
Weighing up blood-thinners: Is warfarin always the best choice?
medicalxpress.com, 17 October 2013
Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.
Tiny Leadless Pacemaker Earns CE Mark Approval
medscape.com, 14 October 2013
ST PAUL, MN - St Jude Medical today announced that the leadless pacemaker (Nanostim), an intracardiac device that has done away with arguably their most problematic component, has been given CE Mark approval for sale in Europe.
CHA2DS2-VASc Score Best for Stroke Risk Assessment in AF
medscape.com, September 2013
Further data confirming that the CHA2DS2-VASc score is preferable to the CHADS2 score in identifying patients with atrial fibrillation (AF) at very low risk for stroke who do not need anticoagulation have come from a large German registry study.
Pediatric atrial fibrillation, rare, but has serious complications risk and high recurrence rates
medicalxpress.com, 7 October 2013
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated heart disease), researchers found a nearly 40% recurrence rate and that AF in the young is accompanied by substantial symptoms.
Biotronik Releases Ilesto DX ICD/CRT-D in US
medgadget.com, 7 October 2013
Having received FDA approval for the Ilesto family of implantable cardioverter-defibrillator (ICD) / cardiac resynchronization therapy defibrillator (CRT-D) devices, BIOTRONIK is launching the Ilesto DX platform in the US.
Improved Survival Among Danish Cardiac-Arrest Patients
theheart.org, 1 October 2013
COPENHAGEN, DENMARK — More and more individuals in Denmark are surviving out-of-hospital cardiac arrest, possibly because of an increase in bystanders performing cardiopulmonary resuscitation (CPR), according to the results of a new study.
Framingham Heart Study Celebrates 65 Years
theheart.org, 3 October 2013
FRAMINGHAM, MA — The Framingham Heart Study (FHS), the longest-running study of cardiovascular disease and its risk factors, is turning 65 years old next week.
Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin
tctmd.com, 3 October 2013
Patients with atrial fibrillation (A-fib) or venous thromboembolism (VTE) who experience major bleeding on the direct thrombin inhibitor dabigatran require a shorter intensive care stay and show a trend for lower mortality than do similar patients on warfarin, according to a review of comparative trials published online September 30, 2013, ahead of print in Circulation.
VIDEO: ESC 2013 - Highlights on arrhythmia and device therapy
cxvascular.com, 17 September 2013
Christophe Leclercq, Rennes, France, chairperson of two European Society of Cardiology (ESC) 2013 sessions in cardiac resynchronisation therapy, speaks about this year’s congress highlights on arrhythmia and device therapy and also what is expected from the ESC congress 2014 in the electrophysiology field.
Sports and arrhythmias: to screen or not to screen
cxvascular.com, 17 September 2013
Screening athletes for the risk of sudden cardiac arrest has been a topic of discussion for many years. Jacob Tfelt-Hansen, author of a Danish study on this subject, gave an overview about different positions and studies that favour or disfavour this practice. He will be speaking on this at Venice Arrhythmias (27–29 October, Venice, Italy).
"Off hours" limit access to AEDs in cardiac arrest
theheart.org, 17 September 2013
Despite widespread placement of automated external defibrillators (AEDs) in one European city, more than half of all cardiac arrests occurred during hours when access to the lifesaving devices is not possible, according to the results of a new study.
Team discovers patient-specific cure for dangerous heart rhythm disorder
medicalxpress.com, 17 September 2013
The National Heart Centre Singapore (NHCS) research team has successfully and completely reversed the effects of the hERG (human ether-a-go-go-related gene) mutation in long QT syndrome 2 (LQTS 2) in patient-specific heart cells, scoring a world's first.
Bad medicine: atrial fibrillation
BMJ.com, 17 September 2013
Last week, our sister charity AF Association responded to an article in the British Medical Journal entitled ‘Bad medicine: atrial fibrillation’ which claimed that the effectiveness of anticoagulation to prevent stroke in AF was overstated. A comprehensive rebuttal of these claims, from the charity's Medical Advisory Committee, has been successfully acknowledged and published online in the BMJ.
Please can we call upon your support to click the ‘like’ button for the letter on the BMJ website. The more ‘likes’ received, the more likely the response will be included in the weekly print issue of the BMJ.
Please like and show your support here
Caution over use of catheter ablation for atrial fibrillation
BMJ.com, 16 September 2013
Read the response and challenge from Dr Gareth J Wynn and Dr Dhiraj Gupta to this article, first published in the British Medical Journal on Friday 14th September 2013.
Mass AF screening flags stroke risk
theheart.org, 13 September 2013
Systematic screening of more than 25 000 individuals aged 75 to 76 identified untreated AF in 5%, putting them at increased stroke risk, preliminary findings of the STROKESTOP study show.
One-Year Data From Global Atrial Fibrillation (AF) Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
sacbee,com, 3 September 2013
One-year outcomes data from the first cohort of the Global Anticoagulant Registry in the FIELD (GARFIELD), an innovative, independent academic research initiative, provide insights into the elevated stroke risk among subpopulations of patients with atrial fibrillation (AF).
Finding the least disruptive approach to tachy-brady syndrome: AF ablation vs pacemaker/drugs
theheart.org, 2 September 2013
One effect of becoming an AF ablation doctor is that you implant fewer pacemakers. Why would this be?
ECHO-CRT: Resynchronization no help, may be harmful in narrow-QRS heart failure
theheart.org, 3 September 2013
Amsterdam, the Netherlands - No, cardiac resynchronization therapy (CRT) will not improve outcomes in patients with narrow QRS intervals (ie, <130 ms) who nonetheless have evidence of ventricular dyssynchrony by echocardiographic criteria. In fact, it may actually increase the risk of cardiovascular death.
ESC: CRT No Help, Maybe Harmful with Short QRS
medpagetoday.com, 3 September 2013
AMSTERDAM - Cardiac resynchronization therapy (CRT) might harm patients with moderate-to-severe heart failure who have a short QRS duration, a randomized trial showed.
GPs undertreat women with AF
sciencecodex.com, 1 September 2013
Amsterdam, The Netherlands - Saturday 31 August 2013: General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France.
Out-of-hospital cardiac arrest survival just 7 percent
sciencecodex.com, 1 September 2013
Amsterdam, The Netherlands – Sunday 1 September 2013: Survival for out-of-hospital cardiac arrest is just 7%, according to research presented at ESC Congress 2013 by Professor Xavier Jouven and Dr Wulfran Bougouin from France.
ESC: Home Monitoring of HF; MRI for Afib Ablation
medpagetoday.com, 1 September 2013
AMSTERDAM - Among the Hot Line presentations at the European Society of Cardiology meeting were a trial looking at telemonitoring of patients with heart failure and a study examining the association between atrial fibrosis and outcomes in patients with atrial fibrillation.
LINC: Similar outcomes with mechanical and manual CPR
theheart.org, 1 September 2013
Amsterdam, the Netherlands - Mechanical chest compressions with the LUCAS device (Physio-Control/Jolife) was as effective as but not more effective than manual compressions for delivering cardiopulmonary resuscitation (CPR) to patients in cardiac arrest in the LINC study.
Mass Screening Identifies Untreated AF in 5% of 75-76 Year Olds
sciencedaily.com, 31 August 2013
Mass screening in more than 25,000 Swedish residents has identified untreated atrial fibrillation in 5 percent of 75-76 year olds, putting them at increased stroke risk.
With or without AF, risk of first stroke rises with risk-factor prevalence
theheart.org, 31 August 2013
Amsterdam, the Netherlands - As the number of ischemic-stroke risk factors goes up in persons without a history of stroke or atrial fibrillation (AF), so does the risk of stroke—so much so that with at least three risk factors, the stroke risk rises to rival that in patients with AF, suggests an analysis of more than four million persons in healthcare registries across Denmark.
CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk
medicalxpress.com, 1 September 2013
The CHADS2 stroke risk scores 0 or 1 assign more than one-third of patients in atrial fibrillation with stroke to low or intermediate risk not mandating oral anticoagulation, according to research presented at ESC Congress 2013 today by Professor Michael Nabauer from Germany.
Pacemaker for slow heart rhythm restores life expectancy
medicalxpress.com, 2 September 2013
Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients.
Framingham Heart Study funding cut by 40%
theheart.org, 28 August 2013
Boston, MA - The longest-running US trial of cardiovascular disease has seen its funding slashed by 40%, and while the Framingham Heart Study (FHS) is still open and ongoing, there will be layoffs later this year and clinical examinations and laboratory activities will be eliminated.
Tailored Afib Care Called For
medpagetoday.com, 28 August 2013
Emerging technology might provide a more personalized approach to help reduce the death and morbidity in atrial fibrillation patients, according to a European consensus statement.
Under-the-Skin ICD Affirmed Safe, Effective
medpagetoday.com, 27 August 2013
The subcutaneous implantable cardioverter-defibrillator (ICD) was safe and effective in the full pivotal trial results finally being published, but the device still has limitations.
ICD/pacemaker implantation: Continued warfarin outperforms bridging with LMWH
theheart.org, 19 August 2013
The seemingly counterintuitive results of the BRUISE trial—which show that continued anticoagulation using warfarin is better than bridging with low-molecular-weight heparin (LMWH)—remind us of the ever-evolving nature of medicine. Will the novel oral anticoagulants prove to be even safer than warfarin? Trials are under way.
Screening to identify unknown atrial fibrillation
thrombosis-online.com, April 2013
Atrial fibrillation (AF) is associated with a significantly increased
stroke risk which is highly preventable with appropriate oral anticoagulant therapy (OAC). However, AF may be asymptomatic and unrecognised prior to stroke.
First patients enrolled in new study design of ARTISAN-AF trial for the treatment of atrial fibrillation
cxvascular.com, 6 August 2013
On 5 August, Hansen Medical announced that the first patients have been successfully enrolled in the new study design of its ARTISAN-AF study, a pivotal clinical trial evaluating the use of Hansen Medical’s Artisan family of control catheters with its Sensei X Robotic Catheter System for treatment of atrial fibrillation.
Single-chamber ICDs with novel detection algorithms show low inappropriate shock rate
cxvascular.com, 7 August 2013
Primary results from the PainFree SST study have shown that 97.6% of patients were free from inappropriate shocks with single-chamber implantable cardioverter defibrillators (ICDs) at one year of implantation.
Heart Rhythm Congress 2013
arwatch.co.uk, August 2013
Delegates are invited to attend the eighth annual Heart Rhythm Congress (HRC) at the International Convention Centre (ICC) in Birmingham UK from 20-23 October 2013.
AF-A Medical Advisory Committee member Dr Andrew Grace joins Arrhythmia & Electrophysiology Review
8 August 2013, London – Arrhythmia & Electrophysiology Review today announces the appointment of Dr Andrew Grace to the position of Deputy Editor – Arrhythmia Mechanisms / Basic Science.
Dr Grace serves as a Consultant Cardiologist at Papworth Hospital Cambridge and as Research Group Head in the Department of Biochemistry at the University of Cambridge. Clinically he has a general electrophysiology practice focussing on catheter ablation techniques for atrial fibrillation and has overseen the development of one of the UK’s largest clinical practices for cardiac arrhythmia management. His pre-clinical research program has taken a systems approach to studying arrhythmia mechanisms. Prior to his current roles, Dr Grace trained in medicine at St Thomas’ Hospital in London, and completed his PhD in Cambridge before undertaking post-doctoral studies as a Fulbright Scholar at the University of California San Diego.
On the appointment, Dr Demosthenes Katritsis, Editor-in-Chief of AER, commented, "It gives us great pleasure to welcome Dr Grace to the position of Deputy Editor – Arrhythmia Mechanisms / Basic Science. Dr Grace has a reputation of international standing in this field and I am sure that his guidance will be invaluable in assisting AER in fulfilling its aims of providing trusted teaching reviews of real educational value for both the arrhythmologist and general cardiologist."
Consensus statement on paediatric arrhythmias released by ESC and AEPC
escardio.org, 18 July 2013
A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) and the Association for European Paediatric and Congenital Cardiology (AEPC).
Cardiac Ablation: Linking Outcomes for NICE (CALON) project launched
CALON is a project which will link patient information from different sources to give improved information on cardiac ablation. The project is being conducted on behalf of NICE, who make recommendations about whether interventional procedures are safe and effective enough for routine use. NICE is interested in assessing the feasability and usefulness of linking patient records from existing sources of data.
View August newsletter
NHS England publishes its response to consultation on specialised service specifications and commissioning policies
NHS England has published its response, Consultation on Specialised Services Specifications and Commissioning Policies 2013/14: Summary and Response from NHS England, to consultation earlier this year on the service specifications and commissioning policies which support its specialised commissioning function.
Our sister charity, AF Association (AF-A) would like to thank all who responded to the draft statements on the LAAO procedure in early January and those who were part of the Consultation Review meeting on 4 June.
Visceral fat adds (a little) to BMI prediction of CV risk: Framingham analysis
theheart.org, 16 July 2013
Visceral adiposity as measured by multidetector computed tomography (CT) was positively and independently correlated with risk of CVD events and incident cancer in a Framingham Heart Study cohort clinically free of both types of disease at baseline. Follow-up extended as long as 7.4 years with a median of five years.
Availability of cardiac CT streamlines cath lab use, lowers costs
theheart.org, 17 July 2013
In a study of young individuals seen at a military center who had chest pain but were at low to moderate risk of having an MI, the percentage of patients sent for invasive coronary angiography (ICA) dropped by 62% after cardiac computed tomography (CT) became available.
NICE guidance: Myocardial infarction with ST-segment elevation (CG167)
10 July 2013
This clinical guideline offers evidence-based advice on the care and treatment of adults with spontaneous onset of myocardial infarction with ST-segment elevation.
LARIAT procedure prevents stroke in patients who are unable to tolerate blood thinners
news-medical.net, 3 July 2013
Jersey Shore University Medical Center is one of only a handful of hospitals in the country offering the recent FDA-approved LARIAT Suture Delivery Device procedure.
Clinical Governance Resource Pack - Self-monitoring for patients on long-term warfarin
This resource pack provides evidence-based, best practice answers to key issues arising within a clinical governance framework in relation to the provision of support of self-monitoring to patients on long-term warfarin.
Data Reveals Changes in Management of Patients Living With Atrial Fibrillation in Europe
prnewswire.com, 27 June 2013
Baseline data from The PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) highlights advances and existent gaps in current management of thromboembolic events in people with AF.
Towards the ‘holy grail’ of anticoagulant drugs
cam.ac.uk, 17 June 2013A new spin-out company from the University of Cambridge and Addenbrooke’s Hospital, XO1 Ltd, has raised million in funding to develop a new anticoagulant drug which has the potential to save millions of lives by preventing heart attacks and strokes without causing bleeding.
The funding, from leading life science investor Index Ventures, will be used to develop ichorcumab, an antibody invented by researchers from the University and Addenbrooke’s, which targets thrombin, the enzyme responsible for blood clotting.
Physical activity and arrhythmia risk
Arrhythmia Watch, 20 June 2013
There is no statistically significant association between regular physical activity and increased incidence of atrial fibrillation (AF), according to a meta-analysis published recently in Circulation: Arrhythmia and Electrophysiology.
AliveCor Expands Mobile ECG Device Offering to United Kingdom & Ireland
The Wall Street Journal, 24 June 2013
AliveCor, Inc., a premier digital health company, announced today that its Heart Monitor for iPhone 4, 4S and 5 is now available for purchase in the United Kingdom and Ireland. To support the launch, the AliveCor Heart Monitor will be on display at the European Heart Rhythm Association (EHRA) Europace 2013 meeting (booth number H3-B220) in Athens, Greece, beginning June 23.
Market Launch of the BIOTRONIK Ilesto 7 Series - World's First DF4 ICD/CRT-D Series Approved for MR Scans
marketwire.com, 20 June 2013
Biotronik, the leading manufacturer of cardiovascular medical technology celebrating its 50th anniversary this year, announced the European market launch of its Ilesto 7 Series today. Ilesto 7 is the world's first DF4 ICD/CRT series approved for MRI, and includes one of the world's smallest ICDs while also offering the greatest longevity -- up to 11.5 years for the single chamber ICD.
NICE guidance on insertion of a subcutaneous implantable cardioverter defibrillator for prevention of sudden cardiac death
ICD Not to Blame for Higher CV Mortality After Shock
medpagetoday.com, 19 June 2013
Certain inappropriate shocks from an implantable cardioverter defibrillator (ICD) are associated with an increased mortality risk, but it may be the underlying arrhythmia that is more detrimental to patient health, the observational ALTITUDE study found.
Central Commissioning Facility
Regional opportunities with the NIHR Research for Patient Benefit (RfPB) Programme for recommending research applications for funding
Extra corporeal membrane oxygenation (ECMO) devices in all heart attack centres in the UK?
The hearts of the medical, sporting and lay communities were captured by the public cardiac arrest of 24-year-old midfielder Fabrice Muamba, during a football match in March 2012. His case was exceptional in that he survived because expert help was at hand immediately but, sadly, most young victims of sudden cardiac arrest do not live to hospitalisation.
Advice from NICE supports improved commissioning for anticoagulation therapy for adults
The National Institute for Health and Care Excellence (NICE) has today (14 May) issued updated support for commissioners to help them work with clinicians and managers to commission high-quality, evidence-based anticoagulation therapy for adults across England.
Dual-Chamber ICDs May Be Overused
medpagetoday.com, 15 May 2013
Dual-chamber implantable cardioverter-defibrillators (ICDs) dominate, perhaps undeservedly, among primary prevention patients without a clear need for pacing, a U.S. national registry study suggested.
Costlier heart device may not be worth it
health24.com, 16 May 2013
A study shows that the dual-chamber implanted defibrillators may have more complications than single-chamber models.
Systematic screening for atrial fibrillation 'better than routine GP practice'
Pulse, 14 May 2013
Systematic screening in GP practices for atrial fibrillation could identify more people with the disease than routine practice, according to a gold-standard review.
New Data On Boston Scientific’s Atrial Fibrillation ‘Watchman’ Device Could Lift Outlook
trefis.com, 13 May 2013
Boston Scientific’s stock rallied over 5% on Thursday after the medical device maker released the much-awaited four-year follow-up data from the “PROTECT AF” clinical trial pertaining to its “Watchman” devices. In this new data, Watchman exhibited better efficacy over Warfarin in preventing death and strokes in atrial fibrillation patients.
Oral anticoagulants less used in paroxysmal than persistent AF: NCDR data
theheart.org, 9 May 2013
Denver, CO - Cardiologists are significantly less likely to prescribe oral anticoagulation therapy for their patients with paroxysmal, compared with persistent, atrial fibrillation, despite similar thromboembolic risks associated with the two forms of AF, suggests an analysis based on data from the National Cardiovascular Data Registry (NCDR).
Program tweak cuts ICD pacing/shocks in broad population: ADVANCE 3
theheart.org, 7 May 2013
Chicago, IL - Implantable-cardioverter defibrillators (ICDs) programmed with prolonged detection intervals cut the total number of delivered therapies in patients with either primary- or secondary-prevention devices in a large randomized trial .
New Oral Anticoagulant Drugs: A Guide From European Society Of Cardiology
medicalnewstoday.com, 30 April 2013
A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.
Insertion of a subcutaneous implantable cardioverter defibrillator for prevention of sudden cardiac death (IPG454)
The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Insertion of a subcutaneous implantable cardioverter defibrillator for prevention of sudden cardiac death.
Fourteen-fold rise in use of alternatives to warfarin
pulse.co.uk, 18 April 2013
Exclusive GPs are increasingly prescribing the newer anticoagulant alternatives to warfarin for the prevention of stroke, although their uptake has been slower than expected due to cost concerns, Pulse can reveal.
NICE Briefing: A new role for NICE in social care
The National Institute for Health and Care Excellence (NICE) has a new name and new responsibilities to develop guidance and quality standards for social care in England.
Amiodarone associated with increased cancer risk in men
clinicaladvisor.com, 8 April 2013
Men taking the antiarrhythmia drug amiodarone (Nexterone), particularly those with extensive exposure, have an increased risk for cancer, study results indicate.
Invitation to join NICE Quality and Outcomes Framework Advisory Committee
NICE is seeking new members to join its Quality and Outcomes Framework (QOF) Advisory Committee.
Launch of Taking the Pulse report
Stroke is the third largest cause of death in England and costs the NHS £2.8 billion each year. AF is a known risk factor for stroke increasing its risk and severity. This report brings together, for the first time, data and evidence on variations that exist in the diagnosis, treatment and quality of life for patients living with atrial fibrillation (AF) and AF related stroke.
Gender Differences In Symptoms And Care Of Irregular Heartbeats
medicalnewstoday.com, 13 March 2013
Women with atrial fibrilation have more symptoms and lower quality of life than men with the same heart condition, according to an analysis of patients in a large national registry compiled by the Duke Clinical Research Institute.
PREVAIL yanked from ACC program; Watchman device meets safety end point
theheart.org, 10 March 2013
Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with nonvalvular AF appear to give some reassurance on safety issues raised previously.
AliveCor™ Mobile ECG Device for Heart Rhythm Monitoring Now Available by Prescription
businesswire.com, 8 March 2013
AliveCor announced today that its mobile Heart Monitor for iPhone is now available by prescription to enable patients to record their heart rhythm anytime, anywhere.
"Alarming" use of unnecessary ECG monitors, ubiquitous, possibly harmful
theheart.org, 9 March 2013
Beeps, chirps, and alarms are the soundtracks of cardiac care units, but what if all that noise is harming, not helping, patient care?
Appropriate Use Criteria For ICDs And CRT
medicalnewstoday.com, 4 March 2013
The American College of Cardiology and the Heart Rhythm Society, along with key specialty societies, have released appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT).
Resources for networks and senates
Clinical networks and senates will play a key role in the new commissioning system by providing clinical advice and leadership to support local decision making.
Stepwise AF screening in the elderly
arwatch.co.uk, 28 February 2013
Stepwise risk factor-stratified atrial fibrillation (AF) screening in a 75-year old plus population yields a large share of candidates for oral anticoagulant (OAC) treatment, according to a study1 published recently in Circulation.
New stroke prevention treatment recommended by NICE
NICE, 27 February 2013
Hospital patientPatients with atrial fibrilation can now be offered apixaban (Eliquis) as an alternative to warfarin to reduce the risk of stroke and blood clots, says NICE.
FDA approves single-lead implantable cardiac defibrillator
cnet.com, 25 February 2013
The device comes with a cellular-based home monitoring system that allows physicians to detect a range of heart-related events, including silent arrhythmias.
Medical Device Alert: Isoline implantable cardioverter defibrillator (ICD) leads manufactured by Sorin Group Italia Srl (MDA/2013/007)
This Medical Device Alert has been issued as there is a risk of inappropriate shocking, pacing inhibition or shocking inhibition due to internal insulation abrasion when using Isoline implantable cardioverter defibrillator (ICD) leads manufactured by Sorin Group Italia Srl.
Epidemiological study: Use of anticoagulants in the management of atrial fibrillation among general practices in England
nelm.nhs.uk, 7 February 2013
Despite the fact that anticoagulation is very effective in preventing strokes due to atrial fibrillation (AF), there is extensive evidence that anticoagulants (AC) remain underused. The Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) tool is a software suite based on the CHADS2 risk evaluation system, which searches general practice clinical information systems to enable practices to identify patients with a history of AF and review their individual risk profile.
Assessment and treatment of patients with acute unstable bradycardia
Nursing Standard, 31 January 2013
Bradycardia is a slow heart rate that can lead to cardiac arrest or occur after initial resuscitation following cardiac arrest.
Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)
NICE Guidance issued: Jan 2013
Antidepressant Contribution to Arrhythmia Risk Clarified
sciencedaily.com, 29 January 2013
A 2011 warning from the U.S. Food and Drug Administration about the popular antidepressant citalopram (Celexa) left many patients and physicians with more questions than answers.
Most ICD patients know when they'd choose device deactivation, survey says
theheart.org, 28 January 2013
New Haven, CT - More than two-thirds of patients with implantable cardioverter-defibrillators (ICDs) would want their device turned off under some circumstances, such as permanently impaired memory or having an incurable disease, suggests a survey analysis published online today in JAMA Internal Medicine.
The next milestone in ICD therapy: Improving patient education
theheart.org, 28 January 2013
If you implant internal cardiac defibrillators (ICDs) and you care about how well patients understand their devices, you will be disappointed in the results of a study released today in JAMA Internal Medicine.
New defibrillator saves lives without wires going into the heart
cleveland.com, 30 November 2012
CLEVELAND, Ohio -- People who have defibrillators implanted in their chests -- to kick-start their hearts when they go out of rhythm and stop pumping blood -- also have a wire or two that runs from the device to their heart to keep them alive.
New anticoagulant approved by NICE
gponline.com, 23 January 2012
GPs have been handed another alternative to warfarin after NICE gave preliminary approval to a new treatment to prevent stroke in AF.
Boston Scientific treats first patient in atrial fibrillation trial
equities.com, 18 January 2013
Boston Scientific Corporation, a developer, manufacturer and marketer of medical devices, has announced that the first patient has been treated in the ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer open-irrigated temperature ablation catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation.